OptiNose Inc (OPTN)
1.26
-0.03
(-2.33%)
USD |
NASDAQ |
May 17, 16:00
1.26
0.00 (0.00%)
After-Hours: 20:00
OptiNose Revenue (Quarterly): 14.88M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 14.88M |
| December 31, 2023 | 19.86M |
| September 30, 2023 | 19.82M |
| June 30, 2023 | 19.45M |
| March 31, 2023 | 11.85M |
| December 31, 2022 | 20.86M |
| September 30, 2022 | 20.08M |
| June 30, 2022 | 20.58M |
| March 31, 2022 | 14.76M |
| December 31, 2021 | 22.51M |
| September 30, 2021 | 21.83M |
| June 30, 2021 | 18.36M |
| March 31, 2021 | 11.96M |
| Date | Value |
|---|---|
| December 31, 2020 | 16.35M |
| September 30, 2020 | 15.44M |
| June 30, 2020 | 10.27M |
| March 31, 2020 | 7.062M |
| December 31, 2019 | 11.08M |
| September 30, 2019 | 12.40M |
| June 30, 2019 | 6.677M |
| March 31, 2019 | 4.476M |
| December 31, 2018 | 3.023M |
| September 30, 2018 | 1.902M |
| June 30, 2018 | 1.274M |
| March 31, 2018 | 0.865M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
6.677M
Minimum
Jun 2019
22.51M
Maximum
Dec 2021
15.80M
Average
15.89M
Median
Revenue (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -- |
| Viking Therapeutics Inc | -- |
| Zevra Therapeutics Inc | 3.425M |
| CytomX Therapeutics Inc | 41.46M |
| Spero Therapeutics Inc | 4.204M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -14.07M |
| Total Expenses (Quarterly) | 22.96M |
| EPS Diluted (Quarterly) | -0.12 |
| Enterprise Value | 221.44M |
| Gross Profit Margin (Quarterly) | 91.73% |
| Profit Margin (Quarterly) | -94.54% |
| Earnings Yield | -21.43% |
| Normalized Earnings Yield | -22.29 |